Investment Rating - The investment rating for the company is "Hold" with a target price not specified for the next 6 months [1]. Core Insights - The company's 2025 performance met expectations, with a revenue of 25.84 billion yuan, representing a year-on-year growth of 25.08%. The net profit attributable to shareholders was 8.21 billion yuan, up 21.91% year-on-year. The fourth quarter of 2025 saw a revenue of 7.16 billion yuan, a 32.4% increase year-on-year, and a net profit of 1.97 billion yuan, up 36.1% year-on-year [8]. - The company has shown significant growth in its innovative product, the Pulsed Field Ablation (PFA), with over 5,900 procedures completed in 2025. The management's confidence is further highlighted by the recent stock incentive plan [8]. - The company is a leading player in the domestic electrophysiology and vascular intervention market, with a diverse product line and strong performance expected to continue as market demand grows [8]. Financial Performance Summary - **Revenue and Profit Forecasts**: - 2025A: Revenue of 25.84 billion yuan, net profit of 8.21 billion yuan - 2026E: Revenue expected to reach 33.11 billion yuan, net profit of 10.40 billion yuan - 2027E: Revenue projected at 41.05 billion yuan, net profit of 12.74 billion yuan - 2028E: Revenue forecasted at 50.17 billion yuan, net profit of 15.91 billion yuan [3][11]. - **Growth Rates**: - Revenue growth rates are expected to be 25.08% for 2025, 28.15% for 2026, 23.97% for 2027, and 22.22% for 2028 [3]. - Net profit growth rates are projected at 21.91% for 2025, 26.78% for 2026, 22.43% for 2027, and 24.89% for 2028 [3]. - **Earnings Per Share (EPS)**: - EPS is expected to grow from 5.82 yuan in 2025 to 11.28 yuan by 2028 [3]. - **Return on Equity (ROE)**: - ROE is projected to remain stable around 25.80% in 2025, slightly decreasing to 24.76% by 2028 [3]. Product Line Performance - **Electrophysiology Products**: - Revenue for the electrophysiology product line in 2025 was 5.71 billion yuan, a growth of 29.81% year-on-year, driven by product iterations and the PFA product's market penetration [8]. - **Coronary Access Products**: - Revenue reached 13.43 billion yuan, up 27.35% year-on-year, attributed to the increased adoption of second-generation balloon catheters and other product upgrades [8]. - **Peripheral Intervention Products**: - Revenue was 4.56 billion yuan, growing by 29.76%, benefiting from ongoing procurement and the introduction of new products [8]. - **OEM Business**: - Revenue declined to 1.45 billion yuan, a decrease of 12.05%, primarily due to expectations of procurement and a drop in international orders [8].

Group 1 - The company plans to repurchase shares using its own funds, with an amount between 150 million to 200 million yuan, aimed at employee incentives and enhancing investor confidence [1] - The first repurchase was executed on February 11, 2026, with 77,000 shares bought back at a total cost of approximately 18.61 million yuan [1] - The recent opening of the national drug procurement may have indirect effects on the medical device industry, although the company's core business focuses on electrophysiology and interventional devices [1] Group 2 - Huayuan Securities initiated coverage on the company on February 13, 2026, giving it a "buy" rating, with expected compound annual growth rates for revenue and net profit exceeding 24% from 2025 to 2027 [2] - In the past 90 days, four institutions have rated the company, with three giving a "buy" and one an "overweight" rating, indicating positive expectations from analysts [2]

Investment Rating - The report maintains a "Strong Buy" rating for the company [2] Core Insights - The company reported a revenue of 1.214 billion yuan for the first half of 2025, representing a year-on-year growth of 21.26%, with a net profit of 425 million yuan, up 24.11% year-on-year [1] - The company's core product, PFA, has gained rapid acceptance in major hospitals, with over 800 procedures completed [5] - The vascular intervention business continues to expand, with coronary business revenue reaching 654 million yuan, a year-on-year increase of 30.02% [5] - International business revenue grew by 23.84% year-on-year, with a notable 34.56% increase in key overseas markets [5] - The overall gross margin improved to 73.51%, contributing to a net profit margin increase to 34.51% [5] Financial Performance - The company expects revenues of 2.691 billion yuan, 3.475 billion yuan, and 4.553 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 30%, 29%, and 31% [6] - The projected net profit for the same years is 900 million yuan, 1.172 billion yuan, and 1.535 billion yuan, with growth rates of 34%, 30%, and 31% [6] - The company's PE ratios for 2025, 2026, and 2027 are projected to be 44, 34, and 26 respectively [6] Key Financial Ratios - The company's gross margin is expected to improve gradually, reaching 73.3% by 2027 [9] - The net profit margin is projected to stabilize around 33.7% by 2027 [9] - The return on equity (ROE) is expected to increase to 31.6% by 2027 [9]